Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

SPRYCEL 50 MG TABLET

dasatinib
$327.4240per EA
High Outlier

Strength

50 mg/1

Manufacturer

E.R. Squibb & Sons, L.L.C.

NDC

00003052811

Classification

Brand

Dosage Form

TABLET

Route

ORAL

Last Updated

8/20/2025

Active Ingredients

DASATINIB

Approval Type

New Drug (NDA)

FDA Application

NDA021986

On Market Since

6/27/2006

Pharmacological Classes

Cytochrome P450 3A4 Inhibitors
Kinase Inhibitor
Protein Kinase Inhibitors

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

0.0%

1Y

0.0%

3Y

+33.9%

5Y

+33.9%

All

+115.3%

Generic Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.

Related Drugs

Same classification

TIAZAC ER 180 MG CAPSULE
Brand
00187261330•Bausch Health US LLC
$1.5060
per EA
TIAZAC ER 180 MG CAPSULE
Brand
00187261390•Bausch Health US LLC
$1.5060
per EA
TIAZAC ER 360 MG CAPSULE
Brand
00187261630•Bausch Health US LLC
$2.7628
per EA
TIAZAC ER 360 MG CAPSULE
Brand
00187261690•Bausch Health US LLC
$2.7628
per EA
NEORAL 25 MG GELATIN CAPSULE
Brand
00078024615•Novartis Pharmaceuticals Corporation
$2.8879
per EA
KALETRA 80 MG-20 MG/ML SOLN
Brand
00074395646•AbbVie Inc.
$3.1186
per ML
CARDIZEM LA 120 MG TABLET
Brand
00187204530•Bausch Health US LLC
$3.6467
per EA
CARDIZEM LA 120 MG TABLET
Brand
00187204590•Bausch Health US LLC
$3.6467
per EA
CARDIZEM LA 180 MG TABLET
Brand
00187204630•Bausch Health US LLC
$3.8314
per EA
CARDIZEM LA 180 MG TABLET
Brand
00187204690•Bausch Health US LLC
$3.8314
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy